Rx Medicare

AcelRx Pharmaceuticals, Inc. announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab(TM) product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized, placebo-controlled, crossover study is assessment of safety, tolerability and efficacy of ARX-02 relative to placebo in cancer patients experiencing episodic breakthrough pain.

Read More…

Related Posts

• Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
• Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
• AcelRx Announces Successful Completion Of End-of-Phase 2 Meeting On ARX-01, Sufentanil NanoTab PCA System For Post-Operative Pain Management
• Breakthrough Cancer Pain: First Results From Major European Patient Survey
• Instanyl(R) (intranasal Fentanyl Spray) Sets New Standard In Management Of Breakthrough Cancer Pain
• Instanyl Sets New Standard In Management Of Breakthrough Cancer Pain
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• KAI Pharmaceuticals Initiates Third Phase 2a Study In Program To Develop KAI-1678 For The Treatment Of Neuropathic Pain
• KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating A Phase 2a Study For Neuropathic Pain
• Treating Back Pain In Blood Marrow Cancer Patients
• Alkermes Announces Initiation Of Multidose Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
• Acupuncture May Relieve Joint Pain Caused By Some Breast Cancer Treatments
• Hypnosis Can Help Control Pain Among Women With Metastatic Breast Cancer, UB Researcher Finds
• Some parents weigh ‘hastening death’ for children in extreme pain with terminal cancer
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug

Tags: acelrx, breakthrough, cancer, initiation, pain, phase, program

This entry was posted on Friday, April 24th, 2009 at 10:04 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.